Regulus Therapeutics Inc. (RGLS)
Jun 25, 2025 - RGLS was delisted (reason: acquired by Novartis)
8.16
+0.02 (0.25%)
Inactive · Last trade price on Jun 24, 2025

Company Description

Regulus Therapeutics Inc. engages in the development of drugs designed to inhibit dysregulated microRNA targets for the benefit of patients with genetically based orphan diseases.

The company develops farabursen, an anti-miR oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease.

It is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies.

Regulus Therapeutics Inc. was formerly known as Regulus Therapeutics LLC and changed its name to Regulus Therapeutics Inc. in January 2009.

The company was incorporated in 2007 and is based in San Diego, California. As of June 25, 2025, Regulus Therapeutics Inc. operates as a subsidiary of Novartis AG.

Regulus Therapeutics Inc.
Regulus Therapeutics logo
CountryUnited States
Founded2007
IPO DateOct 4, 2012
IndustryBiotechnology
SectorHealthcare
Employees34
CEOJoseph Hagan

Contact Details

Address:
4224 Campus Point Court, Suite 210
San Diego, California 92121
United States
Phone858 202 6300
Websiteregulusrx.com

Stock Details

Ticker SymbolRGLS
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001505512
CUSIP Number75915K309
ISIN NumberUS75915K3095
Employer ID26-4738379
SIC Code2834

Key Executives

NamePosition
Joseph P. Hagan M.B.A.Chief Executive Officer and Director
Dr. Preston S. Klassen M.D., M.H.S.President, Head of Research and Development and Director
Crispina Calsada CPAChief Financial Officer
Daniel J. PenksaVice President of Finance and Controller
Christopher Ray Aker J.D.Senior Vice President, General Counsel and Corporate Secretary
Dr. Claire Susan Padgett M.S., M.T., Ph.D.Senior Vice President of Clinical Operations
Dr. Rekha Garg M.D., M.S.Chief Medical Officer
Edmund Lee Ph.D.Vice President of Translational Medicine

Latest SEC Filings

DateTypeTitle
Jun 25, 2025POS AMPost-Effective amendments for registration statement
Jun 25, 2025POS AMPost-Effective amendments for registration statement
Jun 25, 2025POS AMPost-Effective amendments for registration statement
Jun 25, 2025POS AMPost-Effective amendments for registration statement
Jun 25, 2025POS AMPost-Effective amendments for registration statement
Jun 25, 2025POS AMPost-Effective amendments for registration statement
Jun 25, 2025POS AMPost-Effective amendments for registration statement
Jun 25, 2025POS AMPost-Effective amendments for registration statement
Jun 25, 2025S-8 POSSecurities to be offered to employees in employee benefit plans, post-effective amendments
Jun 25, 2025S-8 POSSecurities to be offered to employees in employee benefit plans, post-effective amendments